CSL Limited (ASX:CSL – Get Free Report) insider Megan Clark purchased 200 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of A$250.06 ($159.27) per share, with a total value of A$50,012.00 ($31,854.78).
Megan Clark also recently made the following trade(s):
- On Wednesday, February 19th, Megan Clark acquired 132 shares of CSL stock. The stock was purchased at an average cost of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).
CSL Price Performance
The company has a market capitalization of $77.43 billion, a P/E ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a current ratio of 1.86 and a quick ratio of 1.68.
CSL Increases Dividend
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Recommended Stories
- Five stocks we like better than CSL
- What Investors Need to Know to Beat the Market
- Can TikTok Stock Picks Really Make You Rich?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- The “Quality” Rotation: Back to Basics Investing
- Which Wall Street Analysts are the Most Accurate?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.